ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0408

Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status

Philip C. Robinson1, Walter P Maksymowych2, Lianne Gensler3, Martin Rudwaleit4, Bengt Hoepken5, Lars Bauer5, Thomas Kumke5, Mindy Kim6 and Atul Deodhar7, 1University of Queensland School of Clinical Medicine, Brisbane, Australia, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 4University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Smyrna, GA, 7Oregon Health & Science University, Portland, OR, USA, Portland, OR

Meeting: ACR Convergence 2022

Keywords: C-reactive protein (CRP), Disease-Modifying Antirheumatic Drugs (Dmards), Inflammation, Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the 52-week (wk) placebo (PBO)-controlled period and the 104 wk open-label (OL) safety follow-up extension (SFE) of the C-axSpAnd study.1 There is, however, a paucity of data on the long-term efficacy of biologics in nr-axSpA according to pts’ baseline MRI and CRP status. This post hoc analysis aimed to evaluate whether pts’ baseline MRI and CRP status impacted long-term (3-year [yr]) clinical responses to CZP.

Methods: C-axSpAnd (NCT02552212) was a 3-yr, phase 3, multicenter study. Adults (N=317) with active nr-axSpA, defined by fulfilling the Assessment of SpondyloArthritis international Society (ASAS) classification criteria and OSI (CRP ≥10 mg/L [CRP+] and/or evidence of sacroiliitis on MRI [MRI+]),2 were randomized 1:1 to PBO or CZP (400 mg at Wks 0, 2, 4 then 200 mg every 2 wks [Q2W]) for 52 wks.3 Those enrolled into the SFE received OL CZP (200 mg Q2W) for an additional 104 wks.Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), ASDAS major improvement (ASDAS-MI; C-axSpAnd primary outcome) and ASAS 40% response (ASAS40) were assessed at Wks 52 and 156 according to prespecified subgroups based on MRI/CRP status (MRI+/CRP+, MRI−/CRP+, MRI+/CRP−). Data are reported as observed case.&

Results: 243/317 (76.7%) pts entered the SFE, 120 initially randomized to CZP (36 MRI+/CRP+, 32 MRI−/CRP+ and 52 MRI+/CRP−) and 123 from the initial PBO group (30 MRI+/CRP+, 34 MRI−/CRP+ and 59 MRI+/CRP−). 206/243 (84.8%) completed the SFE; 102/120 (85.0%) from the group initially randomized to CZP, 104/123 (84.6%) from the initial PBO group.

Among CZP-randomized pts, mean ASDAS was similar at Wks 52 and 156; the percentage achieving ASDAS-MI was lower at Wk 156 compared with Wk 52 across all subgroups (Figure 1). Pts initially randomized to PBO showed improvements in mean ASDAS over time; ASDAS-MI achievement was sustained. The proportion of patients achieving ASDAS-MI was numerically highest in the MRI+/CRP+ subgroup, and lowest in the MRI+/CRP− subgroup.

Similar results were shown for BASDAI, with mean scores for CZP-randomized pts sustained from Wk 52 to Wk 156 across all subgroups (Figure 2). Mean BASDAI decreased from Wk 52 to Wk 156 in pts initially randomized to PBO, at which point the values aligned with those reported for the CZP-randomized group.

In CZP-randomized pts, ASAS40 responses were sustained at Wk 156 compared with Wk 52. An increased percentage of pts achieved ASAS40 in all MRI/CRP subgroups initially randomized to PBO at Wk 156 compared with Wk 52 (Figure 3).

Conclusion: In pts with nr-axSpA and OSI, long-term clinical outcomes achieved after 1 yr were generally sustained at 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI was numerically highest in the MRI+/CRP+ subgroup.References: 1. van der Heijde D. Arthritis Rheumatol 2021;73(suppl 10); 2. Lambert RG. Ann Rheum Dis 2016;75(11):1958–63; 3. Deodhar A. Arthritis Rheumatol 2019;71(7):1101–11.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Robinson, AbbVie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, UCB Pharma, Bristol-Myers Squibb (BMS); W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; L. Gensler, Novartis, Pfizer Inc, UCB Pharma, AbbVie, Eli Lilly, Janssen, Gilead, Moonlake; M. Rudwaleit, AbbVie, Bristol-Myers Squibb (BMS), Boehringer-Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma; B. Hoepken, UCB Pharma; L. Bauer, UCB Pharma; T. Kumke, UCB Pharma; M. Kim, UCB Pharma; A. Deodhar, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB Pharma, Aurinia, Moonlake.

To cite this abstract in AMA style:

Robinson P, Maksymowych W, Gensler L, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, Deodhar A. Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-clinical-outcomes-of-certolizumab-pegol-treatment-in-patients-with-active-non%e2%80%91radiographic-axial-spondyloarthritis-stratified-by-baseline-mri-and-c-reactive-protein-status/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-clinical-outcomes-of-certolizumab-pegol-treatment-in-patients-with-active-non%e2%80%91radiographic-axial-spondyloarthritis-stratified-by-baseline-mri-and-c-reactive-protein-status/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology